Kiniksa Pharmaceuticals Reports Q1 Earnings and Raises 2026 Revenue Guidance
Kiniksa Pharmaceuticals International reported Q1 2026 sales of $214.3 million for ARCALYST and raised full-year revenue guidance to $930 million–$945 million. The company also highlighted strong commercial momentum, with 400 new prescribers and a DTC campaign aimed at increasing patient awareness. Pipeline progress, including phase II data for KPL-387, was also discussed.
Tickers: $KNSA
Topics: ARCALYST Earnings Pharmaceuticals Pipeline Development Revenue Guidance